Developing novel biomarkers to predict Alzheimer's disease

June 26, 2012

Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer's disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.

Alzheimer's disease (AD) is a growing challenge to the health care systems and economies of with millions of patients suffering from this disease and increasing numbers of new cases diagnosed annually with the increasing ageing of populations.

Early detection of prodromal AD is vital both for assessing the efficacy of potential AD as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early associated with progression to Alzheimer's disease may also help in identifying new therapeutic avenues.

In 2010 GE Healthcare entered into "biosignatures initiative" alliance with Janssen Pharmaceutica N.V. (Janssen) to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.

VTT's research professor Matej Orešič said: "We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programs and to further develop our towards a clinical assay applicable in healthcare setting. VTT has over the past years built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE's and Janssen's biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options."

Explore further: Biochemical signature predicts progression to Alzheimer's disease

Related Stories

Biochemical signature predicts progression to Alzheimer's disease

December 14, 2011
A study led by Research Professor Matej Orešič from VTT Technical Research Centre of Finland suggests that Alzheimer's disease is preceded by a molecular signature indicative of hypoxia and up-regulated pentose ...

Study identifies specific bacteria which precede autoimmune diabetes

October 28, 2011
A study led by Matej Oresic from VTT Technical Research Centre of Finland suggests that autoimmune diabetes is preceded by diminished gut microbial diversity of the Clostridium leptum subgroup, elevated plasma leptin and ...

Changes seen in cerebrospinal fluid levels before onset of Alzheimer dementia

January 2, 2012
Cerebrospinal fluid levels of Aβ42 appear to be decreased at least five to 10 years before some patients with mild cognitive impairment develop Alzheimer disease (AD) dementia whereas other spinal fluid levels seem to ...

PET-CT exams help identify cognitive reserve in early-onset Alzheimer's disease

May 2, 2011
A recent study revealed that the "cognitive reserve" in early-onset Alzheimer's disease (AD) and PET-CT examinations can be used to effectively to identify early-onset AD patients.

Pathological aging brains contain the same amyloid plaques as Alzheimer's disease

May 23, 2012
Pathological aging (PA) is used to describe the brains of people which have Alzheimer's disease (AD)-like pathology but where the person showed no signs of cognitive impairment whilst they were alive. New research, published ...

Recommended for you

One step closer toward a treatment for Alzheimer's disease?

October 18, 2017
Scientists at the Massachusetts General Hospital (MGH), in collaboration with colleagues at the University California, San Diego (UCSD), have characterized a new class of drugs as potential therapeutics for Alzheimer's disease ...

New mechanism detected in Alzheimer's disease

October 13, 2017
McGill University researchers have discovered a cellular mechanism that may contribute to the breakdown of communication between neurons in Alzheimer's disease.

Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer's disease

October 13, 2017
Microglia, immune cells that act as the central nervous system's damage sensors, have recently been implicated in Alzheimer's disease.

Green tea extract delivers molecular punch to disrupt formation of neurotoxic species

October 11, 2017
Green tea is widely considered to be beneficial for the brain. The antioxidant and detoxifying properties of green tea extracts help fight catastrophic diseases such as Alzheimer's. However, scientists have never fully understood ...

Menopause triggers metabolic changes in brain that may promote Alzheimer's

October 10, 2017
Menopause causes metabolic changes in the brain that may increase the risk of Alzheimer's disease, a team from Weill Cornell Medicine and the University of Arizona Health Sciences has shown in new research.

Being unaware of memory loss predicts Alzheimer's disease, new study shows

October 10, 2017
While memory loss is an early symptom of Alzheimer's disease, its presence doesn't mean a person will develop dementia. A new study at the Centre for Addiction and Mental Health (CAMH) has found a clinically useful way to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.